Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: biphasic insulin aspart 30
Drug: biphasic insulin aspart 50
Drug: biphasic insulin aspart 70
Drug: insulin aspart

First Posted Date: 2012-01-30

Last Posted Date: 2017-01-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 35

Registration Number: NCT01520831

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: biphasic insulin aspart 30
Drug: sitagliptin
Drug: metformin

First Posted Date: 2012-01-27

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 582

Registration Number: NCT01519674

Locations: 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey

Use of Somatropin in Turner Syndrome

Phase 3

Completed

Conditions: Genetic Disorder
Turner Syndrome

Interventions: Drug: somatropin

First Posted Date: 2012-01-25

Last Posted Date: 2017-02-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 57

Registration Number: NCT01518036

Locations: 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom

Metabolism and Excretion of Liraglutide in Healthy Male Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: liraglutide [3H]

First Posted Date: 2012-01-25

Last Posted Date: 2017-01-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 7

Registration Number: NCT01517568

Locations: 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands

Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: liraglutide
Drug: placebo
Drug: atorvastatin
Drug: griseofulvin
Drug: lisinopril
Drug: digoxin

First Posted Date: 2012-01-25

Last Posted Date: 2017-01-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 70

Registration Number: NCT01518166

Locations: 🇸🇪
Novo Nordisk Investigational Site, Uppsala, Sweden

Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome

Phase 4

Completed

Conditions: Turner Syndrome
Genetic Disorder

Interventions: Drug: somatropin
Drug: oestrogen

First Posted Date: 2012-01-25

Last Posted Date: 2017-01-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 65

Registration Number: NCT01518062

Locations: 🇳🇱
Novo Nordisk Investigational Site, Alphen a/d Rijn, Netherlands

Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: placebo
Drug: paracetamol

First Posted Date: 2012-01-25

Last Posted Date: 2017-01-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 18

Registration Number: NCT01517555

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: placebo

First Posted Date: 2012-01-24

Last Posted Date: 2017-01-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01515592

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: liraglutide
Drug: moxifloxacin
Drug: placebo
Procedure: electrocardiogram (ECG)

First Posted Date: 2012-01-24

Last Posted Date: 2017-01-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 64

Registration Number: NCT01516255

Locations: 🇺🇸
Novo Nordisk Investigational Site, Fargo, North Dakota, United States

Comparison of Two Liraglutide Formulations in Healthy Subjects

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: liraglutide

First Posted Date: 2012-01-24

Last Posted Date: 2015-01-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 22

Registration Number: NCT01515579

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy